| Systematic (IUPAC) name | |
|---|---|
| (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-([2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl)-1H-benzimidazole-7-carboxylate | |
| Clinical data | |
| Trade names | Edarbi |
| AHFS/Drugs.com | Consumer Drug Information |
| MedlinePlus | a611028 |
| Licence data | US FDA:link |
| Pregnancy cat. | C (1st trimester) D (2nd/3rd trimester) (US) |
| Legal status | ℞-only (US) |
| Routes | Oral |
| Identifiers | |
| CAS number | 863031-21-4 |
| ATC code | C09CA09 |
| PubChem | CID 11238823 |
| ChemSpider | 9413866 |
| UNII | F9NUX55P23 |
| Chemical data | |
| Formula | C30H24N4O8 |
| Mol. mass | 568.53 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
Azilsartan (INN, codenamed TAK-536) is an angiotensin II receptor antagonist used in the treatment of hypertension that was developed by Takeda.
It is marketed in tablet form under the trade name Edarbi as the prodrug azilsartan medoxomil (INN, codenamed TAK-491). On 25 February 2011, the U.S. Food and Drug Administration (FDA) approved azilsartan medoxomil for the treatment of high blood pressure in adults.[1] On March 8, 2012, Health Canada approved the drug for mild to moderate essential hypertension. [2]
Azilsartan medoxomil lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone.
|
||||||||||||||||
| This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)